Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
In his second letter to Illumina shareholders this week, Icahn wrote the "only path forward is for Grail to be divested". Illumina said on Monday it will divest Grail, which it purchased in 2021, if it loses its appeal to the European Commission where regulators said last year they intend to require Illumina to unwind the $7.1 billion takeover. Icahn, who owns 1.4% of Illumina, launched a proxy fight earlier this week and is seeking three board seats at the company after weeks of private discussions with Illumina sputtered.